Loading
A phase 3 trial of ipilimumab and nivolumab in lung cancer, run by M.D. Anderson Cancer Center, active but no longer recruiting.
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT03391869 by M.D. Anderson Cancer Center, with a registry enrolment figure of 339 participants, started 2017-12-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: Ipilimumab; Local Consolidation Therapy; Nivolumab; Quality-of-Life Assessment; Radiation Therapy; Therapeutic Conventional Surgery. Conditions listed: Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS) in overall population; OS in oligometastatic subgroup. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed non-small cell lung cancer; if a diagnostic biopsy is available, a pre-treatment biopsy is not required". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Adenocarcinoma of the lung, Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab and the tag lung-deep-dive.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Adenocarcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ipilimumab, Lung cancer trials open today (registry snapshot), Nivolumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.